(Q38046580)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Neoadjuvant treatments for triple-negative breast cancer (TNBC) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

triple-negative breast cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

M Martin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

23 Suppl 6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

vi35-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012300%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Management of triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Primary systemic therapy in operable breast cancer: clinical data and biological fall-out

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Changing end points in breast-cancer drug approval--the Avastin story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS193